股本结构
单位：万股
| 公告日期 | 2020-05-07 | 2020-05-07 | 2020-03-12 | 2020-01-24 | 2020-03-12 | 2019-11-12 |
|---|---|---|---|---|---|---|
| 证券总股本 | 726.32 | 725.90 | 725.92 | 584.62 | 346.60 | 271.60 |
| 普通股本 | 726.32 | 725.90 | 725.92 | 584.62 | 346.60 | 271.60 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2020-05-06 | 2020-03-31 | 2020-03-09 | 2020-01-24 | 2019-12-31 | 2019-09-30 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2020-05-07 | 726.32 | 未披露 | 定期报告 | 2020-05-06 |
| 2020-05-07 | 725.90 | 未披露 |
更多>>
From December 31, 2019 to March 31, 2020
Issuance of common stock and prefunded warrants under a concurrent private placement and registered direct offering, less issuance costs
Issuance of common stock from warrant exercise
|
2020-03-31 |
| 2020-03-12 | 725.92 | 未披露 | 定期报告 | 2020-03-09 |
| 2020-01-24 | 584.62 | 未披露 |
更多>>
1.Common stock offered by us pursuant to this prospectus supplement 2,380,105 shares of common stock.
2.The number of shares of our common stock to be outstanding after this offering and the concurrent private placement is based on 3,466,058 shares of our common stock issued and outstanding as of December 31, 2019
|
2020-01-24 |
| 2020-03-12 | 346.60 | 未披露 |
更多>>
from December 31, 2018 to December 31, 2019
Issuance of common stock under stock plans
Issuance of common stock and prefunded warrants under registered direct offering, less issuance costs
Issuance of common stock from warrant exercise
Issuance of common stock under employee stock purchase plan
|
2019-12-31 |
| 2019-11-01 | 301.58 | 未披露 | 定期报告 | 2019-11-01 |
| 2019-11-12 | 271.60 | 未披露 | 定期报告 | 2019-09-30 |
| 2019-09-26 | 270.00 | 未披露 |
更多>>
Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, announced today that it will effect a 1-for-20 reverse stock split of its common stock that will be effective at 5:00 p.m. Eastern Time today. The Company's common stock will begin trading on a split-adjusted basis when the market opens on September 27, 2019 under the existing symbol “TTPH”. The reverse stock split will reduce the number of shares of common stock issued and outstanding from approximately 54.3 million to approximately 2.7 million.
|
2019-09-27 |
| 2019-08-07 | 5431.65 | 未披露 | 定期报告 | 2019-07-01 |
| 2019-08-08 | 5431.70 | 未披露 |
更多>>
From March 31, 2019 to June 30, 2019
Issuance of common stock under stock plans
Issuance of common stock under employee stock purchase plan
|
2019-06-30 |
| 2019-04-26 | 5426.38 | 未披露 | 定期报告 | 2019-04-18 |
| 2019-05-08 | 5374.60 | 未披露 |
更多>>
from December 31, 2018 to March 31, 2019
Issuance of common stock under stock plans
|
2019-03-31 |
| 2019-04-26 | 5374.55 | 未披露 | 定期报告 | 2019-03-01 |
| 2019-03-15 | 5368.00 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Issuance of common stock under "at-the-market" equity offering sales agreement, less issuance costs
Issuance of common stock under employee stock purchase plan
|
2018-12-31 |
| 2018-11-09 | 5362.57 | 未披露 | 定期报告 | 2018-11-08 |
| 2018-11-09 | 5354.50 | 未披露 | 定期报告 | 2018-09-30 |
| 2018-08-02 | 5285.86 | 未披露 | 定期报告 | 2018-08-01 |
| 2018-08-02 | 5285.10 | 未披露 | 定期报告 | 2018-06-30 |
| 2018-04-20 | 5163.00 | 未披露 | 定期报告 | 2018-04-06 |
| 2018-05-03 | 5163.00 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-03-06 | 5163.00 | 未披露 | 定期报告 | 2018-03-02 |
| 2018-01-25 | 5159.48 | 未披露 | 定期报告 | 2018-01-24 |
| 2018-03-06 | 5145.80 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Issuance of common stock under stock plans
Issuance of common stock from follow-on public offering less underwriters discounts and issuance costs
Issuance of common stock under "at-the-market" equity offering sales agreement, less issuance costs
Issuance of common stock under employee stock purchase plan
|
2017-12-31 |
| 2017-11-01 | 5141.46 | 未披露 | 定期报告 | 2017-10-31 |
| 2017-11-01 | 5118.00 | 未披露 | 定期报告 | 2017-09-30 |
| 2017-08-02 | 5105.34 | 未披露 |
更多>>
On August 2, 2017, Company sold 10,000,000 shares of common stock in an underwritten public offering at an offering price to the public of $6.50 per share, resulting in net proceeds to Company of $60.9 million after deducting underwriting discounts and commissions of $3.9 million and offering costs of $0.2 million.
|
2017-08-02 |
| 2017-08-02 | 4001.20 | 未披露 |
更多>>
As of June 30, 2017, Company had sold 2,894,156 shares under the Agreement at an average price of $7.81 per share and we had received aggregate cash proceeds of $21.7 million, after deducting the sales commissions and offering expenses.
|
2017-06-30 |
| 2017-05-08 | 3795.68 | 未披露 | 定期报告 | 2017-05-04 |
| 2017-04-21 | 3774.90 | 未披露 | 定期报告 | 2017-04-05 |
| 2017-05-08 | 3774.90 | 未披露 | 定期报告 | 2017-03-31 |
| 2017-03-13 | 3705.71 | 未披露 | 定期报告 | 2017-03-10 |
| 2017-03-13 | 3694.20 | 未披露 |
更多>>
from December 31, 2015 to December 31, 2016
Exercise of stock options and vesting of restricted stock units
Shares issued in connection with employee stock purchase plan
|
2016-12-31 |
| 2016-11-03 | 3690.44 | 未披露 | 定期报告 | 2016-11-03 |
| 2016-11-03 | 3669.90 | 未披露 | 定期报告 | 2016-09-30 |
| 2016-08-04 | 3669.86 | 未披露 | 定期报告 | 2016-08-02 |
| 2016-08-04 | 3665.40 | 未披露 | 定期报告 | 2016-06-30 |
| 2016-04-29 | 3660.61 | 未披露 | 定期报告 | 2016-04-14 |
| 2016-05-04 | 3659.90 | 未披露 | 定期报告 | 2016-03-31 |
| 2016-02-25 | 3659.92 | 未披露 | 定期报告 | 2016-02-19 |
| 2016-02-25 | 3658.50 | 未披露 |
更多>>
from December 31, 2014 to December 31, 2015
Exercise of stock options
Issuance of common stock from follow-on public offering (net of underwriters discounts and issuance costs of $10,924)
Issuance of common stock under employee stock purchase plan
|
2015-12-31 |
| 2015-11-02 | 3654.23 | 未披露 | 定期报告 | 2015-10-30 |
| 2015-11-02 | 3652.20 | 未披露 | 定期报告 | 2015-09-30 |
| 2015-08-06 | 3642.07 | 未披露 | 定期报告 | 2015-08-01 |
| 2015-08-06 | 3636.90 | 未披露 | 定期报告 | 2015-06-30 |
| 2015-05-07 | 3612.99 | 未披露 | 定期报告 | 2015-05-01 |
| 2015-04-30 | 3609.17 | 未披露 | 定期报告 | 2015-04-14 |
| 2015-05-07 | 3607.20 | 未披露 | 定期报告 | 2015-03-31 |
| 2015-03-06 | 3097.66 | 未披露 | 定期报告 | 2015-02-28 |
| 2015-03-06 | 3080.60 | 未披露 |
更多>>
from December 31, 2013 to December 31, 2014
Issuance of common stock from follow-on public offering (net of underwriters discounts and issuance costs of $5,542)
Issuance of common stock under employee stock purchase plan
Issuance of common stock from warrant exercise
Exercise of stock options
|
2014-12-31 |
| 2014-11-10 | 3065.75 | 未披露 |
更多>>
In October 2014, the Company completed the sale of 4,542,500 shares of common stock in a follow-on public offering.
|
2014-11-04 |
| 2014-11-10 | 2601.70 | 未披露 | 定期报告 | 2014-09-30 |
| 2014-08-12 | 2595.32 | 未披露 | 定期报告 | 2014-07-31 |
| 2014-08-12 | 2590.90 | 未披露 | 定期报告 | 2014-06-30 |
| 2014-05-12 | 2583.30 | 未披露 | 定期报告 | 2014-04-30 |
| 2014-04-29 | 2583.00 | 未披露 | 定期报告 | 2014-04-14 |
| 2014-05-12 | 2581.30 | 未披露 | 定期报告 | 2014-03-31 |
| 2014-03-06 | 2579.04 | 未披露 | 定期报告 | 2014-02-28 |
| 2014-03-06 | 2562.93 | 未披露 |
更多>>
from December 31, 2012 to December 31, 2013
Issuance of Series B convertible preferred stock, net of issuance costs of $117,171
Vesting of restricted stock
Exercise of stock options
|
2013-12-31 |
| 2013-11-14 | 2517.63 | 未披露 | 定期报告 | 2013-11-13 |
| 2013-11-04 | 2067.63 | 未披露 | 定期报告 | 2013-09-30 |
| 2013-05-13 | 2067.19 | 未披露 | 定期报告 | 2013-05-09 |
| 2013-05-13 | 1987.41 | 未披露 |
更多>>
On February 28, 2013, the Company’s board of directors approved an amendment to the Company’s certificate of incorporation to effect a 1-for-29 reverse split of its Common Stock (the Reverse Split).
|
2013-03-31 |
| 2013-03-20 | 1986.80 | 未披露 |
更多>>
1.gives effect to a 1-for-29 reverse split of our common stock effected on March 5, 2013;
2.gives effect to the automatic conversion of all outstanding shares of our preferred stock into 8,828,438 shares of our common stock upon the closing of this offering.
|
2013-03-20 |
| 2013-03-05 | 32.52 | 25602.50 |
更多>>
On February 28, 2013, effect a 1-for-29 reverse split of its Common Stock
|
2013-02-28 |
| 2013-02-21 | 943.25 | 25602.50 |
更多>>
from December 31, 2011 to December 31, 2012
Exercise of stock options
|
2012-12-31 |
| 2013-02-11 | 932.27 | 25602.50 |
更多>>
from December 31, 2011 to September 30, 2012
Exercise of stock options
|
2012-09-30 |
From December 31, 2019 to March 31, 2020
Issuance of common stock and prefunded warrants under a concurrent private placement and registered direct offering, less issuance costs
Issuance of common stock from warrant exercise
1.Common stock offered by us pursuant to this prospectus supplement 2,380,105 shares of common stock.
2.The number of shares of our common stock to be outstanding after this offering and the concurrent private placement is based on 3,466,058 shares of our common stock issued and outstanding as of December 31, 2019
from December 31, 2018 to December 31, 2019
Issuance of common stock under stock plans
Issuance of common stock and prefunded warrants under registered direct offering, less issuance costs
Issuance of common stock from warrant exercise
Issuance of common stock under employee stock purchase plan
Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, announced today that it will effect a 1-for-20 reverse stock split of its common stock that will be effective at 5:00 p.m. Eastern Time today. The Company's common stock will begin trading on a split-adjusted basis when the market opens on September 27, 2019 under the existing symbol “TTPH”. The reverse stock split will reduce the number of shares of common stock issued and outstanding from approximately 54.3 million to approximately 2.7 million.
From March 31, 2019 to June 30, 2019
Issuance of common stock under stock plans
Issuance of common stock under employee stock purchase plan
from December 31, 2018 to March 31, 2019
Issuance of common stock under stock plans
from December 31, 2017 to December 31, 2018
Issuance of common stock under "at-the-market" equity offering sales agreement, less issuance costs
Issuance of common stock under employee stock purchase plan
from December 31, 2016 to December 31, 2017
Issuance of common stock under stock plans
Issuance of common stock from follow-on public offering less underwriters discounts and issuance costs
Issuance of common stock under "at-the-market" equity offering sales agreement, less issuance costs
Issuance of common stock under employee stock purchase plan
On August 2, 2017, Company sold 10,000,000 shares of common stock in an underwritten public offering at an offering price to the public of $6.50 per share, resulting in net proceeds to Company of $60.9 million after deducting underwriting discounts and commissions of $3.9 million and offering costs of $0.2 million.
As of June 30, 2017, Company had sold 2,894,156 shares under the Agreement at an average price of $7.81 per share and we had received aggregate cash proceeds of $21.7 million, after deducting the sales commissions and offering expenses.
from December 31, 2015 to December 31, 2016
Exercise of stock options and vesting of restricted stock units
Shares issued in connection with employee stock purchase plan
from December 31, 2014 to December 31, 2015
Exercise of stock options
Issuance of common stock from follow-on public offering (net of underwriters discounts and issuance costs of $10,924)
Issuance of common stock under employee stock purchase plan
from December 31, 2013 to December 31, 2014
Issuance of common stock from follow-on public offering (net of underwriters discounts and issuance costs of $5,542)
Issuance of common stock under employee stock purchase plan
Issuance of common stock from warrant exercise
Exercise of stock options
In October 2014, the Company completed the sale of 4,542,500 shares of common stock in a follow-on public offering.
from December 31, 2012 to December 31, 2013
Issuance of Series B convertible preferred stock, net of issuance costs of $117,171
Vesting of restricted stock
Exercise of stock options
On February 28, 2013, the Company’s board of directors approved an amendment to the Company’s certificate of incorporation to effect a 1-for-29 reverse split of its Common Stock (the Reverse Split).
1.gives effect to a 1-for-29 reverse split of our common stock effected on March 5, 2013;
2.gives effect to the automatic conversion of all outstanding shares of our preferred stock into 8,828,438 shares of our common stock upon the closing of this offering.
On February 28, 2013, effect a 1-for-29 reverse split of its Common Stock
from December 31, 2011 to December 31, 2012
Exercise of stock options
from December 31, 2011 to September 30, 2012
Exercise of stock options